P
Precigen Inc (PGEN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$4.30
-0.24 (-5.29%)
Market Cap: $1.63B
Last updated: Nov 17, 2026 at 11:06 AM ET
Precigen Inc (PGEN) P/E Ratio & Valuation Multiples
Precigen (PGEN) trades at 98.6x trailing earnings and 9.9x sales. Its P/S of 9.9x is below its 5-year median of 50.7x. Its forward P/E is 7.0x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 1308.6% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 98.6x |
| Forward P/E | 7.0x |
| Price to sales | 9.9x |
| Price to book | 18.4x |
| EV/EBITDA | 42.2x |
| PEG | N/A |
| FCF yield | -4.8% |
Historical Medians
Against its 10-year medians, its P/S is 52.2% below 20.7x and its P/B is 291.5% above 4.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 9.9x | 50.7x | 20.7x |
| P/B | 18.4x | 4.8x | 4.7x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 2.4x in 2017 to 347.0x in 2018.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $4.18 | 145.1x | 62.6x |
| 2024 | $1.12 | 74.5x | 8.5x |
| 2023 | $1.34 | 52.2x | 2.8x |
| 2022 | $1.52 | 11.3x | 2.5x |
| 2021 | $3.71 | 44.9x | 6.9x |
| 2020 | $10.20 | 45.7x | 27.1x |
| 2019 | $5.48 | 9.8x | 11.9x |
| 2018 | $6.54 | 347.0x | 2.4x |
| 2017 | $11.52 | 2.4x | 2.6x |
| 2016 | $24.30 | 15.0x | 5.1x |
Frequently Asked Questions About PGEN
What is PGEN's forward P/E ratio?
Precigen has a forward P/E ratio of 7.0x.
What is PGEN's price to sales ratio?
Precigen has a price to sales ratio of 9.9x.
PGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors